A&R:核输出的小分子抑制剂通过调节浆细胞生成和存活来改善狼疮

2022-08-26 MedSci原创 MedSci原创

该团队的研究结果为选择性核输出抑制剂化合物的治疗潜力提供了支持,因为它们靶向在狼疮发病机制中至关重要的几种分子和细胞途径,包括浆细胞产生的自身抗体。

目的研究最近批准用于治疗难治性浆细胞(PC)恶性肿瘤的选择性核输出抑制剂(SINE 化合物)可能在治疗狼疮方面具有潜力的假设。

方法SINE化合物KPT-350或载体对照处理雌性NZB/NZW小鼠。收集组织样本并使用标准标记通过流式细胞术进行分析。通过确定蛋白尿评分和肾脏标本的组织学分析来监测肾炎。通过酶联免疫吸附试验测量血清抗双链DNA(抗dsDNA)水平,并通过酶联免疫斑点试验评估分泌IgGdsDNA特异性抗体分泌细胞的总数。

结果KPT-350在疾病的早期和晚期消除了鼠狼疮性肾炎,并迅速损害了生发中心(GC)中自身反应性浆细胞的生成SINE化合物抑制基质细胞产生NF-κB驱动的稳态趋化因子,改变脾B细胞和T细胞的战略定位,并显著减少滤泡辅助T细胞、生发中心B细胞和自身反应性浆细胞计数。KPT-350还降低了狼疮易感小鼠肾脏中参与浆细胞存活和募集的细胞因子和趋化因子的水平。在人类扁桃体的生发中心、狼疮患者的脾B细胞和狼疮性肾炎患者肾脏的多个B细胞亚群中检测到了SINE化合物的靶点核输出蛋白1

结论总的来说,该团队的研究结果选择性核输出抑制剂化合物的治疗潜力提供了支持,因为它们靶向在狼疮发病机制中至关重要的几种分子和细胞途径,包括浆细胞产生的自身抗体。

出处:Rangel-Moreno, J., Garcia-Hernandez, M.d.l.L., Owen, T., Barnard, J., Becerril-Villanueva, E., Kashyap, T., Argueta, C., Gamboa-Dominguez, A., Tamir, S., Landesman, Y., Goldman, B.I., Ritchlin, C.T. and Anolik, J.H. (2022), Small Molecule Inhibitors of Nuclear Export and the Amelioration of Lupus by Modulation of Plasma Cell Generation and Survival. Arthritis Rheumatol, 74: 1363-1375. https://doi.org/10.1002/art.42128

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1914739, encodeId=32421914e39a2, content=<a href='/topic/show?id=84d7469559b' target=_blank style='color:#2F92EE;'>#小分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46955, encryptionId=84d7469559b, topicName=小分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Fri May 12 10:16:12 CST 2023, time=2023-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853039, encodeId=d07b1853039b8, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Oct 15 23:16:12 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678220, encodeId=5da616e8220e1, content=<a href='/topic/show?id=f34c46963cc' target=_blank style='color:#2F92EE;'>#小分子抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46963, encryptionId=f34c46963cc, topicName=小分子抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b6f27658858, createdName=lqrandywkz, createdTime=Fri Jul 21 07:16:12 CST 2023, time=2023-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241216, encodeId=4ffc1241216d1, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95318294883, createdName=ms7000001091436823, createdTime=Fri Aug 26 20:52:09 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387580, encodeId=e210138e58021, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Thu Aug 25 00:16:12 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466645, encodeId=7fc11466645e8, content=<a href='/topic/show?id=8d3e65434d4' target=_blank style='color:#2F92EE;'>#浆细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65434, encryptionId=8d3e65434d4, topicName=浆细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=181c6846356, createdName=huangshifeng, createdTime=Thu Aug 25 00:16:12 CST 2022, time=2022-08-25, status=1, ipAttribution=)]
    2023-05-12 宋威
  2. [GetPortalCommentsPageByObjectIdResponse(id=1914739, encodeId=32421914e39a2, content=<a href='/topic/show?id=84d7469559b' target=_blank style='color:#2F92EE;'>#小分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46955, encryptionId=84d7469559b, topicName=小分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Fri May 12 10:16:12 CST 2023, time=2023-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853039, encodeId=d07b1853039b8, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Oct 15 23:16:12 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678220, encodeId=5da616e8220e1, content=<a href='/topic/show?id=f34c46963cc' target=_blank style='color:#2F92EE;'>#小分子抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46963, encryptionId=f34c46963cc, topicName=小分子抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b6f27658858, createdName=lqrandywkz, createdTime=Fri Jul 21 07:16:12 CST 2023, time=2023-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241216, encodeId=4ffc1241216d1, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95318294883, createdName=ms7000001091436823, createdTime=Fri Aug 26 20:52:09 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387580, encodeId=e210138e58021, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Thu Aug 25 00:16:12 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466645, encodeId=7fc11466645e8, content=<a href='/topic/show?id=8d3e65434d4' target=_blank style='color:#2F92EE;'>#浆细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65434, encryptionId=8d3e65434d4, topicName=浆细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=181c6846356, createdName=huangshifeng, createdTime=Thu Aug 25 00:16:12 CST 2022, time=2022-08-25, status=1, ipAttribution=)]
    2022-10-15 jklm09
  3. [GetPortalCommentsPageByObjectIdResponse(id=1914739, encodeId=32421914e39a2, content=<a href='/topic/show?id=84d7469559b' target=_blank style='color:#2F92EE;'>#小分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46955, encryptionId=84d7469559b, topicName=小分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Fri May 12 10:16:12 CST 2023, time=2023-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853039, encodeId=d07b1853039b8, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Oct 15 23:16:12 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678220, encodeId=5da616e8220e1, content=<a href='/topic/show?id=f34c46963cc' target=_blank style='color:#2F92EE;'>#小分子抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46963, encryptionId=f34c46963cc, topicName=小分子抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b6f27658858, createdName=lqrandywkz, createdTime=Fri Jul 21 07:16:12 CST 2023, time=2023-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241216, encodeId=4ffc1241216d1, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95318294883, createdName=ms7000001091436823, createdTime=Fri Aug 26 20:52:09 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387580, encodeId=e210138e58021, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Thu Aug 25 00:16:12 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466645, encodeId=7fc11466645e8, content=<a href='/topic/show?id=8d3e65434d4' target=_blank style='color:#2F92EE;'>#浆细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65434, encryptionId=8d3e65434d4, topicName=浆细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=181c6846356, createdName=huangshifeng, createdTime=Thu Aug 25 00:16:12 CST 2022, time=2022-08-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1914739, encodeId=32421914e39a2, content=<a href='/topic/show?id=84d7469559b' target=_blank style='color:#2F92EE;'>#小分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46955, encryptionId=84d7469559b, topicName=小分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Fri May 12 10:16:12 CST 2023, time=2023-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853039, encodeId=d07b1853039b8, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Oct 15 23:16:12 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678220, encodeId=5da616e8220e1, content=<a href='/topic/show?id=f34c46963cc' target=_blank style='color:#2F92EE;'>#小分子抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46963, encryptionId=f34c46963cc, topicName=小分子抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b6f27658858, createdName=lqrandywkz, createdTime=Fri Jul 21 07:16:12 CST 2023, time=2023-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241216, encodeId=4ffc1241216d1, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95318294883, createdName=ms7000001091436823, createdTime=Fri Aug 26 20:52:09 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387580, encodeId=e210138e58021, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Thu Aug 25 00:16:12 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466645, encodeId=7fc11466645e8, content=<a href='/topic/show?id=8d3e65434d4' target=_blank style='color:#2F92EE;'>#浆细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65434, encryptionId=8d3e65434d4, topicName=浆细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=181c6846356, createdName=huangshifeng, createdTime=Thu Aug 25 00:16:12 CST 2022, time=2022-08-25, status=1, ipAttribution=)]
    2022-08-26 ms7000001091436823

    挺好的

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1914739, encodeId=32421914e39a2, content=<a href='/topic/show?id=84d7469559b' target=_blank style='color:#2F92EE;'>#小分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46955, encryptionId=84d7469559b, topicName=小分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Fri May 12 10:16:12 CST 2023, time=2023-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853039, encodeId=d07b1853039b8, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Oct 15 23:16:12 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678220, encodeId=5da616e8220e1, content=<a href='/topic/show?id=f34c46963cc' target=_blank style='color:#2F92EE;'>#小分子抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46963, encryptionId=f34c46963cc, topicName=小分子抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b6f27658858, createdName=lqrandywkz, createdTime=Fri Jul 21 07:16:12 CST 2023, time=2023-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241216, encodeId=4ffc1241216d1, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95318294883, createdName=ms7000001091436823, createdTime=Fri Aug 26 20:52:09 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387580, encodeId=e210138e58021, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Thu Aug 25 00:16:12 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466645, encodeId=7fc11466645e8, content=<a href='/topic/show?id=8d3e65434d4' target=_blank style='color:#2F92EE;'>#浆细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65434, encryptionId=8d3e65434d4, topicName=浆细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=181c6846356, createdName=huangshifeng, createdTime=Thu Aug 25 00:16:12 CST 2022, time=2022-08-25, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1914739, encodeId=32421914e39a2, content=<a href='/topic/show?id=84d7469559b' target=_blank style='color:#2F92EE;'>#小分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46955, encryptionId=84d7469559b, topicName=小分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Fri May 12 10:16:12 CST 2023, time=2023-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853039, encodeId=d07b1853039b8, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Oct 15 23:16:12 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678220, encodeId=5da616e8220e1, content=<a href='/topic/show?id=f34c46963cc' target=_blank style='color:#2F92EE;'>#小分子抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46963, encryptionId=f34c46963cc, topicName=小分子抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b6f27658858, createdName=lqrandywkz, createdTime=Fri Jul 21 07:16:12 CST 2023, time=2023-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241216, encodeId=4ffc1241216d1, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95318294883, createdName=ms7000001091436823, createdTime=Fri Aug 26 20:52:09 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387580, encodeId=e210138e58021, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Thu Aug 25 00:16:12 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466645, encodeId=7fc11466645e8, content=<a href='/topic/show?id=8d3e65434d4' target=_blank style='color:#2F92EE;'>#浆细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65434, encryptionId=8d3e65434d4, topicName=浆细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=181c6846356, createdName=huangshifeng, createdTime=Thu Aug 25 00:16:12 CST 2022, time=2022-08-25, status=1, ipAttribution=)]

相关资讯

5.10 世界狼疮日,一文总结如何科学战狼

5月10日“世界狼疮日”,这是一个为了红斑狼疮病人而存在的日子,一文梳理系统性红斑狼疮如何诊疗。

Rheumatology:尿CD163是儿童狼疮性肾炎中活动性肾病的标志物

评估尿液CD163检测儿童期系统性红斑狼疮(cSLE)患者疾病活动性的实用性。

Biomed Pharmacother:中药及天然提取物治疗狼疮性肾炎的进展

狼疮性肾炎(LN)是一种多系统受累的自身免疫性疾病,也是系统性红斑狼疮(SLE)中最严重的器官损害形式之一,主要由肾小球内免疫复合物的形成和沉积引起。超过50%的SLE患者有肾损害的临床表现。

Kidney Int Rep:他克莫司联合霉酚酸酯和糖皮质激素三联免疫抑制治疗狼疮性肾炎的远期疗效

狼疮肾炎是系统性红斑狼疮患者常见而严重的器官损害,仍然是慢性肾脏病的重要原因,与许多发病率和死亡率有关。

Transl Res:CD11b激动剂--狼疮性肾炎治疗新方法

疮性肾炎(LN)是系统性红斑狼疮(SLE)的一种并发症,在此,我们对CD11b及其在SLE和LN中的相关性作一综述,并建议CD11b的变构激活是治疗SLE和LN的潜在新策略。

Arthritis Res Ther:羟氯喹可加重狼疮性肾炎并发急性肾损伤。

狼疮肾炎(LN)是肾脏炎症的一种形式,是系统性红斑狼疮(SLE)的常见和严重并发症,其特征是蛋白尿、血尿,甚至肾功能损害。LN可导致终末期肾病(ESRD),是SLE的主要死亡原因。